Biovest International, Inc.
Corporate Headquarters
8500 Evergreen Blvd. NW
Minneapolis
Minnesota
55433
United States
Tel: 763-786-0302
Fax: 763-786-0915
Website: http://www.biovest.com/
Email: investor@biovest.com
97 articles about Biovest International, Inc.
-
Stellar Biotechnologies, Inc. And Biovest International, Inc. Sign KLH Supply Agreement For BiovaxID Immunotherapy For Follicular Non-Hodgkin's Lymphoma
10/24/2014
-
Biovest International, Inc. CEO Carlos F. Santos, Ph.D. To Present At The Phacilitate Immunotherapy Forum
1/27/2014
-
European Medicines Agency Accepts Marketing Authorization Application For Biovest International, Inc.’s Cancer Vaccine For Treatment Of Non-Hodgkin’s Follicular Lymphoma
1/13/2014
-
Biovest International, Inc. Emerges From Bankruptcy and Taps New CEO
7/16/2013
-
Request to Appoint Tustee or Examiner in Biovest International, Inc. Case Denied
4/16/2013
-
Biovest International, Inc. Files for Bankruptcy
3/8/2013
-
Accentia Biopharmaceuticals, Biovest International, Inc. Shrink Losses, Default on Debt
12/27/2012
-
Biovest International, Inc. Names Lymphoma Key Opinion Leader From MD Anderson Cancer Center to Scientific Advisory Board
9/11/2012
-
Biovest International, Inc. Conducts End of Phase III Review With FDA of BiovaxID™ as Consolidation Therapy in Non-Hodgkin's Lymphoma
8/14/2012
-
Biovest International, Inc. Advances Process Seeking European Marketing Approval for BiovaxID Personalized Lymphoma Vaccine
7/30/2012
-
Biovest International, Inc. Release: National Cancer Institute Study Demonstrates Significant Overall Survival and Time-to-Next-Treatment Benefits for BiovaxID® Cancer Vaccine Following Rituximab-Chemotherapy in Mantle Cell Lymphoma Study
6/7/2012
-
Biovest International, Inc. Announces BiovaxID® American Society of Clinical Oncology Abstract Available On-line; National Cancer Institute to Present Cancer Vaccine Data from Mantle Cell Lymphoma Study
5/18/2012
-
Biovest International, Inc. Retains Ferghana Partners to Evaluate Strategic Transactions
5/16/2012
-
Biovest International, Inc. to Seek Marketing Approval in the EU for BiovaxID® Personalized Lymphoma Cancer Vaccine
5/14/2012
-
Biovest International, Inc. Announces that New Clinical Data for BiovaxID® Personalized Cancer Vaccine will be Presented by National Cancer Institute at American Society of Clinical Oncology
5/3/2012
-
Biovest International, Inc. and US Army Enter into Collaborative Agreement to Develop Novel Bioreactor Systems as Platform Technology for Production of Anti-Viral Vaccines and Drugs
4/23/2012
-
Biovest International, Inc. Interviewed by OneMedRadio Regarding Global Regulatory Strategy to Seek Approvals for BiovaxID® Cancer Vaccine
4/19/2012
-
Biovest International, Inc. to Seek Marketing Approval for BiovaxID® Personalized Lymphoma Cancer Vaccine in Canada
4/10/2012
-
Biovest International, Inc. Announces International Members of its Cancer Vaccine Scientific Advisory Board
4/3/2012
-
Biovest International, Inc. Establishes World Class Scientific Advisory Board Comprised of Key Opinion Leaders in the Fields of Cancer Immunotherapy, Bioinformatics and Cell Culture Systems
3/27/2012